← back to search

Robert Verity

Imperial College London · GB
Area of research
Public Health, Environmental and Occupational Health · Modeling and Simulation
Research interest
Research interests include Malaria Research and Control, COVID-19 epidemiological studies, Mosquito-borne diseases and control, and SARS-CoV-2 and COVID-19 Research.
h-index
42
citations
20,291
works
149
NIH funding
primary concept
Medicine
email

Recent publications

Artemisinin Partial Resistance Mutations in Zanzibar and Tanzania Suggest Regional Spread and African Origins, 2023.
2026cited by 4position: contributordoi
The burden of malaria-attributable maternal anaemia and the impact of preventive treatment across sub-Saharan Africa
Nature Health 2026cited by 2position: middledoi
The burden of malaria-attributable maternal anaemia and the impact of preventive treatment across sub-Saharan Africa.
2026cited by 0position: contributordoi
Artemisinin Partial Resistance Mutations in Zanzibar and Tanzania Suggest Regional Spread and African Origins, 2023
2025cited by 3position: contributordoi
The burden of malaria-attributable maternal anemia and the impact of IPTp across sub-Saharan Africa
2025cited by 1position: contributordoi
Mapping the prevalence of molecular markers of <i>Plasmodium falciparum</i> artemisinin partial resistance in Africa: a spatial-temporal modelling study
2025cited by 1position: contributordoi
Towards an open analysis ecosystem for <i>Plasmodium</i> genomic epidemiology
2025cited by 1position: contributordoi
Towards Setting Minimum and Optimal Data to Report for Malaria Molecular Surveillance with Targeted Sequencing: The “What” and the “Why”
2025cited by 0position: contributordoi
Robert Verity, Samir Bhatt, Anne Cori, Seth Flaxman, and Swapnil Mishra’s contribution to the Discussion of ‘Some statistical aspects of the Covid-19 response’ by Wood et al.
Journal of the Royal Statistical Society Series A: Statistics in Society 2025cited by 0position: contributordoi
Towards Setting Minimum and Optimal Data to Report for Malaria Molecular Surveillance (MMS) with Targeted Sequencing: The “What” and the “Why”
2025cited by 0position: contributordoi
Flexible and cost-effective genomic surveillance of P. falciparum malaria with targeted nanopore sequencing.
2024cited by 37position: contributordoi
Pandemic burden in low-income settings and impact of limited and delayed interventions: A granular modelling analysis of COVID-19 in Kabwe, Zambia
International Journal of Infectious Diseases 2024cited by 2position: middledoi
Strong isolation by distance and evidence of population microstructure reflect ongoing Plasmodium falciparum transmission in Zanzibar
2024cited by 0position: contributordoi
Author response: Strong isolation by distance and evidence of population microstructure reflect ongoing Plasmodium falciparum transmission in Zanzibar
2024cited by 0position: contributordoi
Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England
Nature Communications 2023cited by 42position: middledoi
Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England.
2023cited by 33position: contributordoi
Sampling for malaria molecular surveillance.
2023cited by 18position: contributordoi
coiaf: Directly estimating complexity of infection with allele frequencies.
2023cited by 11position: contributordoi
Author Correction: Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England
Nature Communications 2023cited by 6position: middledoi
Author Correction: Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England.
2023cited by 3position: contributordoi
Strong isolation by distance and evidence of population microstructure reflect ongoing <i>Plasmodium falciparum</i> transmission in Zanzibar
2023cited by 1position: contributordoi
Strong isolation by distance and evidence of population microstructure reflect ongoing Plasmodium falciparum transmission in Zanzibar
2023cited by 0position: contributordoi
Estimating the COVID-19 infection fatality ratio accounting for seroreversion using statistical modelling.
2022cited by 29position: contributordoi
Reassessing Reported Deaths and Estimated Infection Attack Rate during the First 6 Months of the COVID-19 Epidemic, Delhi, India.
2022cited by 4position: contributordoi
Reduction in mobility and COVID-19 transmission.
2021cited by 340position: contributordoi
Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England
Science Translational Medicine 2021cited by 141position: middledoi
Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis
Vaccine 2021cited by 114position: middledoi
Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis
Vaccine 2021cited by 103position: contributordoi
Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England.
2021cited by 101position: contributordoi
Leveraging community mortality indicators to infer COVID-19 mortality and transmission dynamics in Damascus, Syria
Nature Communications 2021cited by 77position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 25 papers (2020–2026)Oliver J. Watson · London School of Hygiene & Tropical Medicine19 papers (2019–2025)Patrick Walker · Imperial College London14 papers (2020–2026)Lucy Okell · National Centre for Infectious Diseases13 papers (2020–2025)Jeffrey A. Bailey · Norwegian Womens Public Health Association13 papers (2018–2025) · 11 papers (2020–2025)Jonathan J. Juliano · University of North Carolina at Chapel Hill11 papers (2018–2026) · 10 papers (2020–2026)Katy A. M. Gaythorpe · World Health Organization10 papers (2020–2023)Natsuko Imai · Wellcome Trust Centre for the History of Medicine10 papers (2020–2023)S. Bhatt · Illumina (United States)9 papers (2019–2022)Sean V. Connelly · University of North Carolina at Chapel Hill9 papers (2023–2026) · 8 papers (2023–2025)H. Juliette T. Unwin · University of Birmingham8 papers (2020–2022) · 8 papers (2020–2025)Richard G. FitzJohn · Institute of Public Health Bengaluru8 papers (2020–2023)Daniel J. Laydon · Imperial College London8 papers (2020–2021)Jessica T. Lin · National Institute of Allergy and Infectious Diseases7 papers (2023–2026)Christopher M Hennelly · University of North Carolina at Chapel Hill6 papers (2023–2025)Varun Goel · University of North Carolina Health Care6 papers (2023–2026)